Concentric Medical Announces First Patients Enrolled In TREVO 2 Clinical Trial

By Concentric Medical Inc., PRNE
Tuesday, February 8, 2011

MOUNTAIN VIEW, California, February 9, 2011 - Concentric Medical, Inc. today announced that the first patients were
enrolled in TREVO 2 (Thrombectomy REvascularization of large Vessel
Occlusions) at Oregon Health & Science University in Portland, Oregon and at
Capital Health in Trenton, New Jersey. Oregon Health & Science enrolled the
first patient in TREVO 2 and Capital Health was first to use the Trevo
device. TREVO 2 is a pivotal clinical trial investigating the safety and
efficacy of Concentric's Trevo(R) Retriever for removing clot from ischemic
stroke patients. The Trevo Retriever is the first device utilizing
Stentriever(TM) technology, a novel method for retrieving clot from the
neurovasculature.

"The continued advancement of retrieval devices is critical to our
abilities to treat stroke patients," said Dr. Erol Veznedaroglu, Director of
Neurosciences and Cerebrovascular and Endovascular Neurosurgery at Capital
Health in Trenton, New Jersey, where Trevo was used for the first time in the
United States
by Dr. Kenneth Liebman, Cerebrovascular Endovascular
Neurosurgeon.

"The experience with Stentriever devices in Europe is very encouraging.
We expect the Trevo Retriever to be more effective and to treat patients more
quickly and ultimately expand endovascular treatment to more stroke patients
in years to come," said Dr. Kenneth Liebman, Director of Neurosurgical
Critical Care at Capital Health, who used the device at the hospital's Stroke
and Cerebrovascular Center of New Jersey.

"It was a true team effort and very exciting for the team to enroll the
first patient in TREVO 2," said Helmi Lutsep, MD who is a Professor of
Neurology at Oregon Health & Science University in Portland, Oregon and
national co-principal investigator of TREVO 2, "With the TREVO 2 study now
underway, we are closer to bringing this important technology to acute
ischemic stroke patients in the US."

The Trevo Retriever is the latest in a portfolio of products from
Concentric Medical, the company that first introduced retrievers for acute
ischemic stroke. The Trevo's Stentriever design leverages the company's long
history of developing clot retrieval technologies for acute ischemic stroke.
Backed by years of research, the Trevo device is the first and only retriever
of its type designed for quick access, rapid clot integration and predictable
clot retrieval in ischemic stroke patients.

The TREVO 2 study will build upon Concentric's previous clot retrieval
trials, MERCI and Multi MERCI, which have provided compelling evidence of the
benefits of retrieving stroke-causing clots from the blood vessels of acute
ischemic stroke patients. Leading acute ischemic stroke centers across North
America
and Europe will be participating.

The Trevo Retriever was launched in Europe and other international
markets in 2010 and has received very positive feedback from clinicians
throughout Europe and the rest of the world.

About Concentric Medical

Concentric Medical is located in Mountain View, California and is the
global leader in the development of endovascular devices for revascularizing
stroke patients. The company manufactures and markets solutions for ischemic
stroke: minimally invasive devices that are delivered into the brain to
restore blood flow by removing blood clots that cause ischemic stroke.
Concentric Medical's devices are available in over 500 leading stroke centers
around the world, and have been the subject of several clinical studies with
total enrollment of over 1,300 patients.

For more information about Concentric Medical, please visit
www.concentric-medical.com.

About the Trevo System

The Trevo System is an innovative, high-performing, easy-to-use thrombus
retrieval system. The main component of the Trevo System introduces
Stentriever(TM) technology, and creates a new generation of retrieval device
to remove clot in acute ischemic stroke. Concentric Medical is the pioneer in
developing devices for ischemic stroke intervention. Since 2002, Concentric
Medical's devices have been used in thousands of stroke patients worldwide.
This experience has been incorporated into the design of the Trevo System to
make thrombus removal an easier, faster and more predictable procedure. The
new Trevo System combined with the Merci(R) portfolio of Retrievers and
DAC(TM) catheters further strengthens Concentric Medical's position as the
global leader in acute ischemic stroke intervention.

About Acute Ischemic Stroke

Stroke is a leading cause of death in the developed world and the leading
cause of serious long-term disability. Ischemic stroke represents over 85% of
strokes and occurs when a blockage or clot develops in one of the arteries
supplying blood to the brain. CE mark for the Merci Retriever was first
obtained in 2002. In 2004 the FDA cleared Concentric Medical's Merci
Retriever(R) for use in patients who are ineligible for IV-tPA or who fail to
respond to IV-tPA therapy. This pioneering device creates a departure from
the historic method of caring for stroke patients and offers physicians and
patients a long-awaited option for stroke intervention.

    Media Contact:
    +1-650-938-2100
    strokeinfo@concentric-medical.com

Concentric Medical, Inc., +1-650-938-2100, strokeinfo at concentric-medical.com

YOUR VIEW POINT
NAME : (REQUIRED)
MAIL : (REQUIRED)
will not be displayed
WEBSITE : (OPTIONAL)
YOUR
COMMENT :